PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies

Summary

This is a single-arm, open-label, one center, dose escalation clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibody and chimeric antigen receptor targeting mesothelin in adult patients with mesothelin positive, recurrent or refractory malignant tumors.

Timeline

Start

2017-02-15

Primary completion

2018-12-01

Completion

2019-02-01

Drugs

Indications